Alpha Emitters
SKU
MRR-742BD517A934
Region
Global
Publication Date
February 2024
Delivery
Immediate
2023
USD 886.95 million
2030
USD 3,211.95 million
2024
USD 1,062.44 million
CAGR
20.18%
Alpha Emitters Market by Radionuclide Type (Actinium-225, Americium-241, Astatine-211), Application (Industrial, Medical) - Global Forecast 2024-2030

[183 Pages Report] The Alpha Emitters Market size was estimated at USD 886.95 million in 2023 and expected to reach USD 1,062.44 million in 2024, at a CAGR 20.18% to reach USD 3,211.95 million by 2030.

Alpha Emitters Market
To learn more about this report, request a free sample copy
Alpha emitters are radionuclides that decay by emitting alpha particles, helium nuclei consisting of two protons and two neutrons. These particles have high energy but a short range, making them effective for targeted radiation therapies, especially in treating cancers where they can destroy malignant cells with minimal damage to surrounding healthy tissue. Key drivers include the rise in cancer cases worldwide, advancement in radiopharmaceuticals, and increasing investments in cancer research. The effectiveness of alpha emitters in targeted alpha therapy (TAT) for treating various cancer types is also a significant driver. The major restraints comprise the high cost of production, stringent regulatory frameworks, and the requirement for sophisticated handling and radiation shielding infrastructure due to the hazardous nature of alpha emitters. Challenges include ensuring safety and minimizing exposure risks during transport and handling, short half-lives of alpha-emitting isotopes that complicate logistics, and the need for collaboration between research institutions and industry for clinical developments. Significant opportunities include various oncological treatments beyond the current limited usage. Innovations in molecule labeling and improvement in isotope production technology may lead to broader commercialization, while partnerships between the public and private sectors could accelerate advancements and adoption of TAT.
Alpha Emitters Market - Global Forecast 2024-2030
To learn more about this report, request a free sample copy
FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Alpha Emitters Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Alpha Emitters Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Alpha Emitters Market, highlighting leading vendors and their innovative profiles. These include Actinium Pharmaceuticals, Inc., Alpha Tau Medical Ltd., Bayer AG, Bracco S.p.A., Cardinal Health, Inc., Eckert & Ziegler, Fusion Pharmaceuticals Inc., Ionetix Corporation, Niowave Inc., Orano Group, RadioMedix, Inc., Siemens Healthineers, and Telix Pharmaceuticals Limited.

Market Segmentation & Coverage

This research report categorizes the Alpha Emitters Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Radionuclide Type
    • Actinium-225
    • Americium-241
    • Astatine-211
    • Plutonium-239
    • Radium-226
    • Uranium-238
  • Application
    • Industrial
    • Medical
      • Bone Metastasis
      • Endocrine Tumors
      • Ovarian Cancer
      • Pancreatic Cancer
      • Prostate Cancer

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Alpha Emitters Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Alpha Emitters Market?
  3. What are the technology trends and regulatory frameworks in the Alpha Emitters Market?
  4. What is the market share of the leading vendors in the Alpha Emitters Market?
  5. Which modes and strategic moves are suitable for entering the Alpha Emitters Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Alpha Emitters Market, by Radionuclide Type
  7. Alpha Emitters Market, by Application
  8. Americas Alpha Emitters Market
  9. Asia-Pacific Alpha Emitters Market
  10. Europe, Middle East & Africa Alpha Emitters Market
  11. Competitive Landscape
  12. Competitive Portfolio
Companies Mentioned
  • Actinium Pharmaceuticals, Inc.
  • Alpha Tau Medical Ltd.
  • Bayer AG
  • Bracco S.p.A.
  • Cardinal Health, Inc.
  • Eckert & Ziegler
  • Fusion Pharmaceuticals Inc.
  • Ionetix Corporation
  • Niowave Inc.
  • Orano Group
  • RadioMedix, Inc.
  • Siemens Healthineers
  • Telix Pharmaceuticals Limited
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Alpha Emitters Market
The Global Alpha Emitters Market size was estimated at USD 886.95 million in 2023 and expected to reach USD 1,062.44 million in 2024.
The Global Alpha Emitters Market to grow USD 3,211.95 million by 2030, at a CAGR of 20.18%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.